NextBio

Help
Description: An alkylating agent of value against both hematologic malignancies and solid tumors. [PubChem]
Drug Type: Small Molecule; Approved
Pharmacology: Lomustine is an alkylating agent of the nitrosourea type. Lomustine and its metabolites interferes with the function of DNA and RNA. It is cell cycle–phase nonspecific. Cancers form when some cells within the body multiply uncontrollably and abnormally. These cells then spread and destroy nearby tissues. Lomustine acts by slowing this process down. It kills cancer cells by damaging the DNA (the genetic material inside the cells) and stops them from dividing.
Mechanism of Action: Lomustine is a highly lipophilic nitrosourea compound which undergoes hydrolysis in vivo to form reactive metabolites. These metabolites cause alkylation and cross-linking of DNA. Other biologic effects include inhibition of DNA synthesis and some cell cycle phase specificity. Nitrosureas generally lack cross-resistance with other alkylating agents.
Indication: Indicated primarily for the treatment of brain tumours. Also for the treatment of breast cancer, Hodgkin's disease, lung cancer, malignant melanoma, multiple myeloma, Non-Hodgkin's lymphomas, ovarian cancer, pancreatic cancer, and renal cell cancer.
Half Life: Approximately 94 minutes, however the metabolites have a serum half-life of 16 to 48 hours.
View Complete Description



Data Correlations | 1 study

Help for Data Correlations View All
Genes category icon Genes
Score Help
FBXW5 100 100
PDIA3 93 93
RBM8A 92 92
RGN 90 90
OLIG1 89 89
C2orf3 87 87
View Top Genes
Biogroups category icon Biogroups
Score Help
T-cell Receptor and CD3 Complex 100 100
Phenylalanine Tyrosine and Tryptoph… 98 98
PTDINS Pathway 97 97
Neuroactive Ligand Receptor Interac… 96 96
Phospholipids As Signalling Interme… 96 96
Steroid hormone receptor 96 96
View Top Biogroups

Individual Studies

  • Liver Pharmacology and Xenobiotic Response Repertoire

    Rattus norvegicus Rattus norvegicus | RNA Expression   RNA Expression

    A definition of RNA expression changes that correlate with liver response programs and an understanding of the similarities and differences in responses to different classes of chemicals would aid in new chemical or drug characterization and add to our understanding of liver biology.

    Authors: Natsoulis G, Pearson CI, Gollub J et al.

    Organization: Iconix Biosciences 325 E. Middlefield Rd…
View All Individual Studies

Associated Researchers

Help for Associated Researchers

Thought leaders and organizations working on research involving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.

View All Author iconAuthors
  • V Gadjeva
  • D J Reed
  • C Pueyo
  • H E May
  • M Weller
View All Clinical trial sponsors icon Clinical Trials Sponsors
  • Children's Oncology Group
  • M.D. Anderson Cancer Center
  • Memorial Sloan-Kettering Cancer Center
  • Radiation Therapy Oncology Group
  • AstraZeneca
View All Affiliations icon Organizations
  • University of Washington
  • Universidad de Córdoba
  • University of Manchester
  • Trakia University
  • University of Tuebingen

Clinical Trials | 72 trials

Help for Clinical Trials View All

Community

Help for Community
NextBio Users

  • No NextBio users were found for “1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea”.
    Complete your user profile with your interests, if you want others to find you within the NextBio community.

NextBio Groups

  • No NextBio groups were found for “1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea”.
    Be the first to start a group and share your interests with others within the NextBio community.

© 2010 NextBio